Non Small Cell Lung Cancer (NSCLC)

Stage I-III, Resectable

Standard Risk

Patients Scheduled for Resection

Completely Resected

ALK Mutation

CIDNA MRD Testing

None at this Time

**LUN0099**
Phase III Study Evaluating Safety & Pharmacokinetics of Pantumumab-IRDye800 as Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures

PI: Lui
Sponsor: Stanford University

**ECOGE4512**
Phase III Crizotinib vs Observation in NSCLC w/ Anaplastic Lymphoma Kinase (ALK) Fusion Protein Tumors

PI: Wakelee
Sponsor: ECOG-ACRIN

**KEY**
- ✔️ Pending
- ☑️ Open for Enrollment
- Link
- Trial Posting
- ☑️ Optional Path
- Extension Study
- Immunotherapy
- Observation Study
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu